950,011 Shares in Maplight Therapeutics, Inc. $MPLT Acquired by 5AM Venture Management LLC

5AM Venture Management LLC purchased a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, HoldingsChannel reports. The fund purchased 950,011 shares of the company’s stock, valued at approximately $16,687,000. Maplight Therapeutics comprises 5.2% of 5AM Venture Management LLC’s portfolio, making the stock its 8th biggest holding.

A number of other institutional investors and hedge funds have also modified their holdings of MPLT. Strs Ohio purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $70,000. New York State Common Retirement Fund purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $93,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $172,000. Finally, Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $205,000.

Insiders Place Their Bets

In related news, insider Jonathan Gillis sold 51,900 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $29.74, for a total value of $1,543,506.00. Following the completion of the sale, the insider directly owned 199,154 shares in the company, valued at approximately $5,922,839.96. This represents a 20.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $713,564.36. Following the completion of the sale, the insider owned 243,450 shares of the company’s stock, valued at approximately $7,001,622. This represents a 9.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 495,244 shares of company stock worth $14,079,461. Corporate insiders own 3.80% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Lifesci Capital raised Maplight Therapeutics to a “strong-buy” rating in a research note on Thursday, May 14th. Needham & Company LLC assumed coverage on Maplight Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating and a $37.00 price target on the stock. TD Cowen assumed coverage on Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating on the stock. Finally, Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $37.78.

Maplight Therapeutics Trading Up 7.5%

Shares of MPLT opened at $29.21 on Thursday. The firm has a market capitalization of $1.24 billion and a P/E ratio of -0.71. The stock’s fifty day simple moving average is $28.69 and its 200 day simple moving average is $21.84. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Sell-side analysts predict that Maplight Therapeutics, Inc. will post -5.04 earnings per share for the current year.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.